Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 19/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31668957 | 0.90 | CHRM1 (0.66) | CHRM1 | |
| SCHEMBL21873393 | 0.90 | CHRM1 (0.66) | CHRM1 | |
| SCHEMBL22212622 | 0.89 | CHRM1 (0.52) | CHRM1 | |
| SCHEMBL21873456 | 0.89 | CHRM1 (0.64) | CHRM1 | |
| SCHEMBL30427991 | 0.89 | CHRM1 (0.64) | CHRM1 | |
| SCHEMBL19932589 | 0.87 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL19932640 | 0.85 | CHRM1 (0.49) | CHRM1 | |
| SCHEMBL21873578 | 0.85 | CHRM1 (0.59) | CHRM1 | |
| SCHEMBL31668987 | 0.85 | CHRM1 (0.59) | CHRM1 | |
| SCHEMBL18725452 | 0.84 | CHRM1 (0.77) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | claimed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | claimed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | claimed |
| EP-3507289-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Suven Life Sciences Limited (IN) | 2019-07-10 | — | — | EP | claimed |
| WO-2018042362-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-03-08 | — | — | WO | claimed |
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | disclosed |
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | disclosed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | disclosed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | disclosed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | disclosed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | disclosed |
| WO-2018042362-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885 |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.